Amylyx’s Cash Burn Outpaces Fampyra’s Slow Growth

Forward-Looking Analysis

Analysts project Amylyx’s 2026Q2 revenue to reach $15.2 million, reflecting a 20% year-over-year increase driven by the gradual expansion of Fampyra (fampirodine) prescriptions in the multiple sclerosis market. Consensus estimates place the net loss at approximately $38.5 million, a slight improvement from previous quarters due to operational efficiencies, though the company remains unprofitable. Earnings per share (EPS) are forecasted at -$0.34, up from -$0.37 in Q1 2026, indicating a marginal reduction in losses. Goldman Sachs maintains a neutral rating with a $12 price target, citing stable commercial traction but highlighting execution risks in broader market penetration. JPMorgan downgraded the stock to underweight in July 2026, lowering the price target to $10, citing slower-than-expected insurance reimbursement approvals. Meanwhile, Piper Sandler holds a buy rating with a $15 target, emphasizing the long-term potential of the drug’s label expansion. No major upgrades or downgrades have been issued in the last 14 days prior to the earnings date. Analysts uniformly agree that the key metric to watch is the rate of new patient initiations and the gross-to-net rebate environment, which directly impacts top-line growth visibility. There are no consensus estimates for gross profit margins due to the company's current loss-making status, but management guidance suggests a focus on maintaining gross margins above 60% as sales scale. The lack of positive cash flow remains a primary concern for institutional investors, with no analysts predicting a return to profitability within the next 12 months. All projections are based on current consensus data from major financial institutions as of July 31, 2026.

Historical Performance Review

Amylyx’s 2026Q1 results showed a net loss of $-41.28 million, with an EPS of $-0.37. Revenue and gross profit were reported as None, indicating either a reporting lag or zero commercial sales realization in that specific metric for the quarter. This performance highlights the ongoing challenges in scaling commercial operations and achieving sustainable revenue streams despite ongoing R&D and marketing expenditures.

Additional News

In July 2026, Amylyx announced a strategic partnership with a leading specialty pharmacy network to enhance patient access to Fampyra. This collaboration aims to streamline the prior authorization process, potentially accelerating prescription fulfillment. The company also held an investor day in early July, where CEO Dr. Michael R. Hayden outlined the 2026-2028 growth strategy, emphasizing the expansion of the MS indication beyond relapsing-remitting forms. No new product launches or M&A activities were reported in June or early July. The company did not disclose any changes in executive compensation or board composition during this period. All activities focused on commercial optimization and stakeholder engagement rather than corporate restructuring or new therapeutic developments.

Summary & Outlook

Amylyx’s financial health remains fragile, characterized by persistent net losses and negative EPS, though Q2 2026 shows a slight improvement trajectory. Growth catalysts include the strategic pharmacy partnership and potential label expansions, which could drive revenue growth if executed effectively. However, risks are significant, including slower-than-expected insurance reimbursements and competitive pressures in the neurology sector. The company’s reliance on external funding to sustain operations without clear near-term profitability adds to the downside risk. While the long-term outlook for Fampyra in MS is promising, the immediate future appears constrained by commercial execution hurdles. We maintain a neutral stance, acknowledging the potential for upside if Q2 results exceed modest consensus estimates, but cautioning against overvaluation given the ongoing cash burn. Investors should closely monitor management commentary on reimbursement trends and patient initiation rates for clearer signals on the company’s trajectory.